HC Wainwright Increases Revance Therapeutics (NASDAQ:RVNC) Price Target to $42.00
Revance Therapeutics (NASDAQ:RVNC – Get Rating) had its price objective upped by investment analysts at HC Wainwright from $29.00 to $42.00 in a note issued to investors on Thursday, The Fly reports
Revance Therapeutics (NASDAQ:RVNC) Hits New 12-Month High Following Analyst Upgrade
Revance Therapeutics, Inc. (NASDAQ:RVNC – Get Rating) shares reached a new 52-week high during mid-day trading on Thursday after HC Wainwright raised their price target on the stock from $29.00 to $4
Revance Therapeutics Price Target Raised to $42.00/Share From $29.00 by HC Wainwright & Co.
Revance Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Revance Therapeutics Is Maintained at Buy by HC Wainwright & Co.
HC Wainwright & Co. Maintains Buy on Revance Therapeutics, Raises Price Target to $42
HC Wainwright & Co. analyst Douglas Tsao maintains Revance Therapeutics (NASDAQ:RVNC) with a Buy and raises the price target from $29 to $42.
Revance Price Target Raised to $42 From $29 at H.C. Wainwright
Analysts Conflicted on These Healthcare Names: Regeneron (REGN) and Revance Therapeutics (RVNC)
Morgan Stanley Adjusts Price Target on Revance Therapeutics to $26 From $25, Maintains Equal-Weight Rating
10:43 AM EST, 01/24/2023 (MT Newswires) -- Revance Therapeutics (RVNC) has an average outperform rating and a price target range of $19 to $65, according to analysts polled by Capital IQ. Price: 33.66
Revance Therapeutics Price Target Raised to $26.00/Share From $25.00 by Morgan Stanley
Revance Therapeutics Price Target Raised to $26.00/Share From $25.00 by Morgan Stanley
Revance Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 01/24/2023 -22.41% Morgan Stanley $25 → $26 Maintains Equal-Weight 01/10/2023 13.4% Needham $35 → $38 Main
Loading...
No Stock Yet